Victory Capital Management
MRNA icon

Victory Capital Management’s Moderna MRNA Stock Holding History

Victory Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.97M Buy
113,860
+60,058
+112% +$3.11M ﹤0.01% 1222
2026
Q1 		$2.73M Buy
53,802
+2,230
+4% +$104K ﹤0.01% 1517
2025
Q4 		$1.52M Buy
51,572
+5,037
+11% +$137K ﹤0.01% 1650
2025
Q3 		$1.2M Sell
46,535
-9,746
-17% -$272K ﹤0.01% 1750
2025
Q2 		$1.55M Sell
56,281
-49,147
-47% -$1.29M ﹤0.01% 1665
2025
Q1 		$2.99M Sell
105,428
-10,504
-9% -$373K ﹤0.01% 1433
2024
Q4 		$4.82M Sell
115,932
-168,512
-59% -$8.05M ﹤0.01% 1274
2024
Q3 		$19M Buy
284,444
+107
+0% +$9.82K 0.02% 859
2024
Q2 		$33.8M Sell
284,337
-15,173
-5% -$1.92M 0.03% 597
2024
Q1 		$31.9M Sell
299,510
-3,622
-1% -$365K 0.03% 645
2023
Q4 		$30.1M Buy
303,132
+21,135
+7% +$1.78M 0.03% 619
2023
Q3 		$29.1M Buy
281,997
+32,371
+13% +$3.61M 0.03% 608
2023
Q2 		$30.3M Sell
249,626
-34,960
-12% -$4.66M 0.03% 603
2023
Q1 		$43.7M Sell
284,586
-183,747
-39% -$30.3M 0.05% 486
2022
Q4 		$84.1M Buy
468,333
+177,047
+61% +$28.9M 0.1% 268
2022
Q3 		$34.4M Buy
291,286
+26,838
+10% +$4.07M 0.04% 601
2022
Q2 		$37.8M Sell
264,448
-11,285
-4% -$1.61M 0.04% 571
2022
Q1 		$37.1M Buy
275,733
+19,330
+8% +$3.25M 0.04% 649
2021
Q4 		$65.1M Buy
256,403
+21,738
+9% +$6.36M 0.06% 455
2021
Q3 		$90.3M Sell
234,665
-54,370
-19% -$20.1M 0.09% 310
2021
Q2 		$67.9M Sell
289,035
-6,672
-2% -$1.19M 0.07% 424
2021
Q1 		$38.7M Sell
295,707
-20,601
-7% -$2.99M 0.04% 656
2020
Q4 		$33M Buy
316,308
+46,409
+17% +$4.7M 0.04% 675
2020
Q3 		$19.1M Buy
269,899
+222,174
+466% +$15.5M 0.02% 819
2020
Q2 		$3.06M Buy
47,725
+10,111
+27% +$554K ﹤0.01% 1303
2020
Q1 		$1.13M Sell
37,614
-3,691
-9% -$84.9K ﹤0.01% 1540
2019
Q4 		$808K Buy
41,305
+10,499
+34% +$186K ﹤0.01% 1807
2019
Q3 		$490K Buy
+30,806
New +$455K ﹤0.01% 1893

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Victory Capital Management's MRNA Position: Q2 2026 in Review

Victory Capital Management increased its Moderna (MRNA) stake by 112% in Q2 2026, buying an estimated $3.11M and bringing the position to 113,860 shares worth $7.97M. The position accounts for ﹤0.01% of the portfolio, ranked #1222.

Victory Capital Management first reported a position in MRNA in Q3 2019 and has held it in 28 quarters since. The position peaked at $90.3M in Q3 2021. 783 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Victory Capital Management held 113,860 shares of Moderna worth $7.97M as of Q2 2026.
  • Victory Capital Management bought 60,058 Moderna shares in Q2 2026, an estimated $3.11M.
  • Moderna made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #1222 holding.
  • Victory Capital Management first reported a position in Moderna in Q3 2019 and has held it in 28 quarters since.
  • Victory Capital Management's Moderna position peaked at $90.3M in Q3 2021.
  • 783 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.